Advertisement


Eric Pujade-Lauraine, MD, PhD, on Ovarian Cancer: Results From the SOLO2 Trial

2017 ESMO Congress

Advertisement

Eric Pujade-Lauraine, MD, PhD, of the Université Paris Descartes, discusses phase III study findings on the efficacy of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer by lines of prior chemotherapy (Abstract 932PD).



Related Videos

Kidney Cancer

Toni K. Choueiri, MD, on RCC: Results From the CABOSUN Trial

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses updated overall survival results on cabozantinib vs sunitinib as initial targeted treatment for patients with metas...

Head and Neck Cancer

Robert I. Haddad, MD, on Head and Neck Cancer: Results of the CheckMate 141 Trial

Robert I. Haddad, MD, of Dana-Farber Cancer Institute, discusses phase III study results on treatment beyond disease progression with nivolumab in patients with recurrent or metast...

Gynecologic Cancers

Sandro Pignata, MD, PhD, on Ovarian and Related Gynecologic Cancers: Expert Perspective on Three Key Trials

Sandro Pignata, MD, PhD, of the Istituto Nazionale dei Tumori, summarizes findings from the ICON8 study on dose-dense chemotherapy integration in first-line epithelial ovarian/fall...

Luis G. Paz-Ares, MD, PhD, on NSCLC: Results of the PACIFIC Trial

Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 De Octubre, discusses phase III study findings on durvalumab after chemoradiation therapy in patients with stage III, locall...

Skin Cancer

Caroline Robert, MD, PhD, on Melanoma: Treatment With Nivolumab and Ipilimumab

Caroline Robert, MD, PhD, of Gustave Roussy, characterizes complete responses in patients with advanced melanoma who received the combination of nivolumab and ipilimumab, or nivolu...

Advertisement

Advertisement



Advertisement